Back to discover
Disease
Hyperuricemia
Late-stage therapeutic developmentEmerging research
2
Publications
18
Clinical trials
1
Related conditions
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2024-10-01World journal of gastroenterology
Research2023-11-20Frontiers in immunology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 3 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
- Q3 2027A Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day Febuxostat
- Q3 2027Effect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)
- Q1 2028SAVE-Care (SGLT2i As Novel Gout Care) Trial
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20282026-06-04
Upcoming trial readoutImportant
Results expected Q3 20272026-04-07
Clinical MilestonesViewHide
Results expected
- 2026-06-04SAVE-Care (SGLT2i As Novel Gout Care) TrialResults expected Q1 2028
- 2026-04-07A Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day FebuxostatResults expected Q3 2027
- 2025-12-15Effect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)Results expected Q3 2027
Recently completed
- 2026-05-30Comparative Study Evaluating the Outcome of Febuxostat Versus Vitamin E in Hyperuricemia Patients With Non-alcoholic Steatohepatitis Without CirrhosisPrimary completion
- 2026-04-01A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and HyperuricemiaPrimary completion
- 2025-12-31Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release TabletsPrimary completion
- 2025-09-04Study on Efficacy and Safety of HR091506 Tablets in Treatment of Gout With Hyperuricemia in AdultsCompleted
Activity timeline7
- 2026-06-04ClinicalSAVE-Care (SGLT2i As Novel Gout Care) TrialResults expected Q1 2028
- 2026-05-30ClinicalComparative Study Evaluating the Outcome of Febuxostat Versus Vitamin E in Hyperuricemia Patients With Non-alcoholic Steatohepatitis Without CirrhosisPrimary completion
- 2026-04-07ClinicalA Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day FebuxostatResults expected Q3 2027
- 2026-04-01ClinicalA Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and HyperuricemiaPrimary completion
- 2025-12-31ClinicalExploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release TabletsPrimary completion
- 2025-12-15ClinicalEffect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)Results expected Q3 2027
- 2025-09-04ClinicalStudy on Efficacy and Safety of HR091506 Tablets in Treatment of Gout With Hyperuricemia in AdultsCompleted
Clinical trials
The current development programme across all trial phases.
Clinical programme
18
6
12
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20232024
Most influential
Major themes8
- Gout2
- Hyperuricemia2
- Arthritis, Gouty1
- Dysbiosis1
- Gastrointestinal Microbiome1
- Prebiotics1
- Probiotics1
- Uric Acid1
Leading journals2
- Frontiers in immunology1
- World journal of gastroenterology1
Leading researchers8
- Chen X1
- Deng Y1
- Durairajan SSK1
- Fu X1
- Iyaswamy A1
- Li C1
- Li D1
- Li Y1
Affiliations (unnormalised)6
- Center for Excellence in Post-Harvest Technologies1
- Guizhou Provincial People's Hospital1
- Karpagam Academy of Higher Education1
- Ministry of Education Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae1
- Nephrology Institute of Guangdong Provincial Academy of Chinese Medical Sciences (NIGH-CM)1
- School of Biomedical Sciences1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.